Cargando…

Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo

Connective tissue growth factor (CCN2) is a major pro-fibrotic factor that frequently acts downstream of transforming growth factor beta (TGF-β)-mediated fibrogenic pathways. Much of our knowledge of CCN2 in fibrosis has come from studies in which its production or activity have been experimentally...

Descripción completa

Detalles Bibliográficos
Autor principal: Brigstock, David R.
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686750/
https://www.ncbi.nlm.nih.gov/pubmed/19294531
http://dx.doi.org/10.1007/s12079-009-0043-9
_version_ 1782167471885647872
author Brigstock, David R.
author_facet Brigstock, David R.
author_sort Brigstock, David R.
collection PubMed
description Connective tissue growth factor (CCN2) is a major pro-fibrotic factor that frequently acts downstream of transforming growth factor beta (TGF-β)-mediated fibrogenic pathways. Much of our knowledge of CCN2 in fibrosis has come from studies in which its production or activity have been experimentally attenuated. These studies, performed both in vitro and in animal models, have demonstrated the utility of pharmacological inhibitors (e.g. tumor necrosis factor alpha (TNF-α), prostaglandins, peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, statins, kinase inhibitors), neutralizing antibodies, antisense oligonucleotides, or small interfering RNA (siRNA) to probe the role of CCN2 in fibrogenic pathways. These investigations have allowed the mechanisms regulating CCN2 production to be more clearly defined, have shown that CCN2 is a rational anti-fibrotic target, and have established a framework for developing effective modalities of therapeutic intervention in vivo.
format Text
id pubmed-2686750
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-26867502009-06-08 Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo Brigstock, David R. J Cell Commun Signal Research Article Connective tissue growth factor (CCN2) is a major pro-fibrotic factor that frequently acts downstream of transforming growth factor beta (TGF-β)-mediated fibrogenic pathways. Much of our knowledge of CCN2 in fibrosis has come from studies in which its production or activity have been experimentally attenuated. These studies, performed both in vitro and in animal models, have demonstrated the utility of pharmacological inhibitors (e.g. tumor necrosis factor alpha (TNF-α), prostaglandins, peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, statins, kinase inhibitors), neutralizing antibodies, antisense oligonucleotides, or small interfering RNA (siRNA) to probe the role of CCN2 in fibrogenic pathways. These investigations have allowed the mechanisms regulating CCN2 production to be more clearly defined, have shown that CCN2 is a rational anti-fibrotic target, and have established a framework for developing effective modalities of therapeutic intervention in vivo. Springer Netherlands 2009-03-18 2009-03 /pmc/articles/PMC2686750/ /pubmed/19294531 http://dx.doi.org/10.1007/s12079-009-0043-9 Text en © The Author(s) 2009
spellingShingle Research Article
Brigstock, David R.
Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title_full Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title_fullStr Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title_full_unstemmed Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title_short Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo
title_sort strategies for blocking the fibrogenic actions of connective tissue growth factor (ccn2): from pharmacological inhibition in vitro to targeted sirna therapy in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686750/
https://www.ncbi.nlm.nih.gov/pubmed/19294531
http://dx.doi.org/10.1007/s12079-009-0043-9
work_keys_str_mv AT brigstockdavidr strategiesforblockingthefibrogenicactionsofconnectivetissuegrowthfactorccn2frompharmacologicalinhibitioninvitrototargetedsirnatherapyinvivo